Co-Diagnostics and JV partner to launch in vitro diagnostic tests in India

Indian regulators recently approved the tests for tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus

Co-Diagnostics - Co-Diagnostics Inc of Utah to formally launch recently approved in vitro diagnostic (IVDs) tests in India
Both companies will roll out the tests at the upcoming India Diagnostic Expo

Co-Diagnostics Inc (NASDAQ:CODX) will be hosting a booth at the upcoming India Diagnostic Expo with its joint venture partner CoSara Diagnostics Pvt Ltd to formally launch their recently approved in vitro diagnostics (IVDs) tests. 

The India Diagnostic Expo, to be held January 4-6 in Hyderabad, India, provides the country’s only diagnostics products and consumables exhibition for the diagnostic services market. 

Co-Diagnostics, based in Salt Lake City, Utah, said that the market is expected to continue growing at 27.5% during the next five years. 

READ: Co-Diagnostics shares climb after eliminating debt and unveiling stock sale

The company’s attendance at the expo follows the announcement last month that the Central Drug Standard Control Organization, India’s regulatory body, approved JV partner CoSara’s tests for tuberculosis, malaria, hepatitis B, hepatitis C and human papillomavirus (HPV).

The licenses and regulatory clearance granted by the regulatory agency allows the five tests to be manufactured and sold for the detection of the respective diseases, with the expo marking their first formal launch in the Indian market.

“We are pleased to officially launch these newly approved diagnostics tests into India,” Co-Diagnostics CEO Dwight Egan said in a statement on Thursday.

“We believe that our patented technology and proprietary design process gives products designed on the CoPrimer platform a competitive edge in such a large and growing market, and the company looks forward to a successful roll-out of these in-demand diagnostics.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham


Quick facts: Co-Diagnostics

Price: 12.46 USD

Market: NASDAQ
Market Cap: $349.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...


Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read